ArticleViruses2026
A Newly Established ELISA for the Surveillance of Rift Valley Fever in Dromedary Camels and Their Owners, Kenya 2018.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
In 2024 Kenya had a population of 4.78 million camels that contributed to the livelihoods of pastoralist communities in northern Kenya. Previous studies in Kenya, Saudi Arabia and eastern Africa demonstrated high seroprevalence of Middle East respiratory syndrome coronavirus (MERS-CoV)-specific antibodies in dromedary camels, as well as sporadic transmission of MERS-CoV from camels to humans. Based on the MERS-CoV data and the very close contact between owners and their camels in northern Kenya, we speculated that camels may also transmit other zoonotic viruses, such as Rift Valley fever virus (RVFV). In this study, 493 camel and 197 human sera were collected in Marsabit, Kenya, through a cross-sectional survey in 2018 and analyzed for the presence of RVFV IgG antibodies using a laboratory-developed indirect enzyme-linked immunosorbent assay (ELISA). Overall, 15.6% of camels and 7.6% of humans were RVFV IgG-positive; IgG-positive camels were predominantly females in large population herds and IgG-positive humans were engaged in farming-related activities and were greater than 18 years old. Of the eight location groups sampled, two had high camel (site 2 and site 6) and two had high human (site 5 and site 6) RVFV seropositivity rates. These data suggest that camelids, such as dromedary camels, may serve as amplifying hosts for vector-borne zoonotic diseases, such as RVFV, and that humans with frequent farming and camel meat, milk, or camel product contact may have increased risk for RVFV exposure or infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.